STING1 and head and neck squamous cell carcinoma: Leveraging the CIVO platform and spatial profiling technology, which allows for drug response assessment at the single-cell level in the preserved TME, the present phase 0 study aimed to evaluate the changes induced by the STING agonist dazostinag alone and in combination with standard-of-care chemotherapy, including carboplatin, paclitaxel, and 5-fluorouracil (5-FU) within the TME of patients with resectable HNSCC.